Recently, low-molecular-weight B-cell growth factor (LMW-BCGF) has been reported to stimulate growth of leukemic cells from B-cell precursor-acute lymphoblastic leukemia (BCP-ALL). We further investigated the effects of LMW-BCGF on proliferation of leukemic clonogenic (progenitor) and nonclonogenic (progeny) cells from children with BCP-ALL (28 patients) and B-cell ALL (two patients).
R of B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) cells may be influenced by lymphokines that regulate growth of normal B-cell precursors. Of primary interest among the B-cell-directed lymphokines is lowmolecular weight B-cell growth factor (LMW-BCGF), a 12 to 20-Kd protein secreted by mitogen-stimulated T cells that promotes S-phase entry of B cells after activation by antigens or anti-IgM antibody.'-4 LMW-BCGF is also able to sustain long-term proliferation of several BCGF-dependent B-cell lines.' Wormann et a1.6 and Uckun et al' reported that LM W-BCGF supports proliferation of BCP-ALL in vitro, and Uckun et al' further demonstrated the presence of specific receptors for this factor on the leukemic cells,
We further examined the role of LMW-BCGF in proliferation of BCP-ALL cells using clonogenic, thymidineincorporation, and cell-cycle assays. We tested the effects of this factor on unseparated bone marrow (BM) cells from ALL patients at diagnosis and relapse, as well as on purified leukemic cells. We also compared this response with that to three other lymphokines (interleukins (1L)-2, -3, and -4) associated with normal lymphoid proliferation.*-" We showed that LMW-BCGF or IL-3, or both are able to support proliferation of leukemic clonogenic (progenitor) and nonclonogenic (progeny) cells from a subset of children with BCP-ALL at diagnosis and relapse. Furthermore, IL-2 and IL-4 slightly enhanced thymidine incorporation by leukemic cells from some patients but did not promote colony growth.
MATERIALS AND METHODS
BM aspirates were studied from 30 patients with either newly diagnosed BCP-ALL (n = 18) or relapse ALL (n = 12), diagnosed by standard immunologic, morphologic, and cytochemical criteria. Specimens contained more than 70% blasts (except for UPN 26 and 27) by immunologic and morphological criteria, and most specimens contained more than 90% blasts after Ficoll-Hypaque separation. All BCP-ALL specimens were positive for terminal deoxynucleotidyl transferase (TdT), the pan-B-cell
Patient specimens.
45). A dose-response effect in colony growth was noted, with an apparent plateau at approximately 2.0 U/mL LMW-BCGF. Colony cells were primarily of leukemic phenotype (CD19+/CD10i). LMW-BCGF also induced significant increases in leukemic progeny cell proliferation as measured by both thymidine incorporation (stimulation indexes of 1.6 to 34) and by cell-cycle assay (percentage S+ G2/M stimulation indexes of 1.6 to 6). LMW-BCGF was more effective in stimulating leukemic proliferation than three recombinant interleukins (rlL-2, rlL-3, rlL-4). although rlL-3 was able to support colony growth in 4 of 11 patients. These results indicate that LMW-BCGF and, to a lesser degree rlL-3, are able to stimulate proliferation of BCP-ALL progenitor and progeny cells, whereas rlL-2 and r l L 4 do not support progenitor cell proliferation and have only marginal effects on leukemic progeny cell proliferation. antigen CD19 (detected by the B43 antibody), and one or more other B-cell-lineage markers. These included the common-ALL antigen CDlO (CALLA), CD20 (Bl), CD21 (B2), CD24 (BA-I), and CD9 (BA-2). BM mononuclear cells were separated by Ficoll-Hypaque centrifugation (1.077 g/mL), and monocytes were removed by I-hour adherence to plastic before the leukemic cells were cultured and phenotyped. Specimens with more than 5% CD3+ T cells were depleted of these cells before culture by a rosetting technique described below.
Marker analysis of BM blasts (prepared as described) was performed using either direct or indirect immunofluorescence and flow cytometry. In addition to phenotyping of leukemic cells with the above antibodies, we enumerated normal B cells by antisurface immunoglobulin (Ig) antibody; T cells by CD3,
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FINDLEY ET AL gated goat F(ab'), anti-mouse IgG; Tago Laboratories, Burlingame, CAI. Cells were incubated for 30 minutes with each antibody, followed by three washes in phosphate-buffered saline (PBS, pH 7.2). Colony cells were also stained for TdT with an immunofluorescence kit (SuperTechs, Bethesda, MD). Background fluorescence was assessed using irrelevant mouse monoclonal IgGs. The percentage of cells expressing each marker was determined with a Zeiss fluorescence microscope and epi-illumination.
Leukemic clonogenic progenitor cells were cultured by the method of Uckun et al. ' BM mononuclear cells 1 x lo5 were cultured in a-MEM (a-minimal essential medium, Fisher Scientific, Atlanta, GA) containing 0.9% methylcellulose, 33% fetal bovine serum (FBS, Hyclone Laboratories, Logan, UT), 1% MEM vitamin solution, 0.5% MEM amino acid solution, 2 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, (all supplements from GIBCO, Grand Island, NY) and 5 x lo-' mol/L 2-mercaptoethano1 (Sigma, St Louis, MO).
In addition, either 10% vol/vol LMW-BCGF, rIL-2, rIL-3, rIL-4, or media was added to the culture. Control cultures without added lymphokine did not contain colonies except in four cases (Table 1) . Final concentrations of lymphokines in the cultures were either 0.1 U/mL (LMW-BCGF) or 100 U/mL (rIL-2, rIL-3, and rIL-4). For Clonogenic assay.
the dose-response experiment, LMW-BCGF was concentrated by ultrafiltration over a IO-Kd molecular weight exclusion membrane (Amicon, Danvers, MA) followed by a second ultrafiltration step over a 30-Kd exclusion membrane to remove excess albumin (present at 1% in the original preparation). By this method, LMW-BCGF was concentrated 20-fold to 20 U/mL; this material (and subsequent dilutions) was used at 10% vol/vol in the cultures. CD19-purified cells were also cultured at up to 0.5 U/mL LMW-BCGF, using Amicon concentrated factor.
Cells were cultured in quadruplicate in 35-mm Petri dishes. Cultures were incubated at 37OC in a humidified 5% CO, incubator for 7 days. Colonies containing more than 20 cells were counted by inverted microscopy and harvested for further morphological and immunophenotyping studies.
BM mononuclear cells were incubated in 96-well flat-bottom plates (2.5 x lo5 cells per well) in RPMl 1640 containing 5% FBS and 15% calf serum. Lymphokines or media were added as described. Experiments were performed in triplicate. Cells were incubated for 48 hours, and then 0.5 pCi tritiated thymidine (New England Nuclear, Boston, MA, specific activity 20 Ci/mmol) was added per well. Cells were incubated for another 24 hours and then harvested on glass-fiber filters using a cell harvester Proliferation assay. 
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(Skatron, Sterling, VA). Filters were dried, and thymidine incorporation was measured by liquid scintillation spectrometry. Partially purified LMW-BCGF was obtained from Cellular Products (Buffalo, NY) and was also provided by Dr F. Uckun, University of Minnesota. LMW-BCGF was obtained from phytohemagglutinin (PHA)-stimulated peripheral blood (PB) mononuclear cell-conditioned media and partially purified by diethylamino ethyl (DEAE) chromatography followed by hydroxylapatite column chromatography. This preparation did not contain detectable amounts of IL-1, IL-2, IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF or interferon-? (IFN-7). as previously reported.' The activity of LMW-BCGF (1.0 U/mL) was quantitated by its ability to stimulate proliferation (ie, thymidine incorporation) of human B cells maintained in long-term ~u l t u r e .~ rIL-3 and rIL-4 were provided by Genetics Institute (Cambridge, MA) and Immunex (Seattle, WA) respectively; rIL-2 was obtained from AMGen (Thousand Oaks, CA).
CD19+ leukemic BM cells were obtained from three patients with more than 95% BM leukemic cells. Cells were stained with anti-CD19 (using B43 antibody, provided by Dr F. Uckun) at 4OC for 30 minutes, washed, and then incubated for 30 minutes with magnetic immunobeads coated with rabbit anti-mouse antibody (Dynabeads M-450; Dyne1 AS, Norway). Bead-rosetted cells were separated with a magnet (Dyne1 MPC-l), and the cells were incubated overnight to allow beads to detach. Sorted cells were at least 99% CD19+, as determined by fluorescence microscopy, and viability (by trypan blue) was at least 90%.
BM mononuclear cells were prepared by the method of Krishan." Cells lo6 were fixed for 30 minutes at 4OC in 95% ethanol. The cells were then incubated with 500 U ribonuclease T1 (Sigma) in 0.2 mol/L phosphate buffer (pH 7) for 30 minutes at 3 7 T . Cells were washed and stained immediately in 0.05 mg/mL propidium iodide (Sigma) in 0.1% Na citrate for 30 minutes at 4°C. Finally, cells were washed and analyzed at 488 nm on a Facstar flow cytometer (Becton Dickinson, Mountain View, CA) for DNA content; lo4 cells were analyzed in each assay. Cryopreserved normal PB mononuclear cells from a pheresis sample were thawed and stained with each assay to determine the position (ie, modal fluorescence) of the GO/Gl -phase peak.
To assess the phenotype of the proliferating cells, a modification of the method of Hollander et all2 was used. Leukemic cells were first surface stained with fluorescein-conjugated CDlO and then fixed in 0.5% paraformaldehyde in PBS (pH 7.2) for 4 hours at 4OC. Cells were then treated with ribonuclease and stained for DNA with propidium iodide as described. Dual-parameter analysis of 5 x lo4
Lymphokines.
Separation ofCDl9' leukemic cells.
Cell-cycle assay.
cells for fluorescein (green) and propidium-iodide (orange) fluorescence was performed at 488 nm on the Facstar.
Increases in thymidine incorporation in the presence of different lymphokines were tested for significance by Student's paired t test. Similarly, the effect of LMW-BCGF on cell-cycle status was analyzed for the group of patients in Table 2 by paired t-test. The degree of correlation between response to the lymphokines as measured by colony growth and thymidine incorporation was measured by calculating the K statistic for those variables, using a matched 2 x 2 table. (UPN 2 and 12) , however, colony cells continued to proliferate when refed with fresh media and lymphokine, and it was possible to establish cell lines. These cell lines had pheno- The cells became independent of exogenous LMW-BCGF after the lines were established, and these cell lines will be the subject of a later report.
Statistical analysis.
RESULTS
Response
To confirm that colonies were derived from leukemic cells, cells from individual and pooled colonies were typed. Results are shown in Table 3 . Most cells from pooled colonies were of leukemic phenotype (TdT+/CD19+/CALLA') and identical to the patient's fresh BM cells. Low percentages of T cells were also detected in some cultures, however, indicating the presence of some T-cell colonies. Typing of individual colonies gave results similar to those in Table 3 (data not shown).
Further confirmation of the leukemic origin of the colonies was obtained by culturing purified CD19+ leukemic cells from three patients (UPN 8, 12, and 30). These CD19+ cells were obtained by rosetting cells labeled with B43 antibody; rosetting was accomplished with magnetic immunobeads, as described in the Materials and Methods section. Comparable numbers of colonies were obtained from the CD19+ cells and the preseparation cells: For UPN 8, there were 167 (CD19') versus 126 (preseparation) colonies per lo5 cells, using 0.5 U/mL LMW-BCGF; for UPN 30, there were 70 (CD19+) versus 116 (preseparation) colonies per lo5 (at 0.2 U/mL LMW-BCGF); for UPN 12,48, (CD19+) versus 35 (preseparation) colonies per lo5 cells using 0.2 U/mL LMW-BCGF.
Colony cells were CDlO' CD19'; no CD3+ T cells were observed in these cultures.
No lymphoblast colonies were obtained from cultures of T-ALL cells or from BCP-ALL cells at diagnosis and relapse without added lymphokine, with the exception of three patients (UPN 16,20, and 30), whose cells produced 53,78, and 14 colonies/105 BM cells, respectively, in cultures with media alone. In addition, one patient with B-ALL (UPN 26) produced spontaneous colonies (840/ lo5 BM cells) without added LMW-BCGF. Spontaneous colony cells from these patients had a phenotype identical to that of fresh leukemic cells (CDlO'/CDl9+). No lymphoblast colonies were observed in cultures from BCP-ALL patients in complete remission; instead, myeloid colonies were usually present. Significantly, no TdT+ colonies were observed in these cultures; this differed markedly from the BCP-ALL cultures during active disease, in which most colony cells were TdT+. The morphology of these colonies differed from that of the lymphoblast colonies, the myeloid cells diffusing outward rather than remaining tightly adherent as in lymphoblast colonies. In addition, cells from myeloid colonies showed maturation to granulocytes and monocyte/macrophages, as determined by Wright's-Giemsa stain.
When we tested three other ILs (rIL-2, rIL-3, and rIL-4) in the BCP-ALL clonogenic assay, we obtained lymphoblast colony growth with rIL-3 (4 of 11 cases, mean 54, median 32), but not with rIL-2 or rIL-4 (Table 4) . One patient 6-ALL . Table 1) . As in the case of the clonogenic assay, a wide variation in response was observed, with stimulation indexes (SIs) ranging from 1.6 to 34 (median SI for responding cases 1.9). There was a significant (P < .001) correlation between response to LMW-BCGF in the clonogenic versus thymidineincorporation assay. Of 23 patients studied with both assays, cells from 21 patients showed a positive correlation between responses in both assays. Cells from 16 patients proliferated in both assays, and cells from five patients (UPN 19, 1 1, 13 , and 28) responded in neither assay. Cells from two patients showed discrepant results between the colony assay and thymidine-incorporation assay: patients UPN 22 and 24 had colony growth but no increase in thymidine incorporation. The discrepant results with these patients reflect differences in response to LMW-BCGF between the leukemic clonogenic progenitor cells and the bulk leukemic (progeny) population. This could result from differential expression of receptors for LMW-BCGF on these two populations of cells derived from these patients.
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To determine the effects of other ILs on DNA synthesis by BCP-ALL cells, we compared the response of 15 patients to LMW-BCGF, rIL-2, rIL-3, and rIL-4 (Table 4 ). In 9 of 15 cases, LMW-BCGF induced a significant increase in DNA synthesis. Median SI for these responding patients was 2.2. Comparable values for the other lymphokines were as follows: rIL-2,3 of 12 patients (median SI 1.9); rIL-3,5 of 14 patients (median SI 1.9); and rIL-4, 1 of 15 patients (SI 2.2).
LMW-BCGF produced greatest stimulation in four patients, and rIL-3 produced greatest stimulation in two patients. In three patients, LMW-BCGF and rIL-3 produced equal stimulation.
Efect of LMW-BCGF on cell-cycle status of BCP-ALL cells. To determine the effect of LMW-BCGF on cell-cycle parameters of BCP-ALL BM cells, the amount of DNA in the cells was quantitated before and after incubation with LMW-BCGF, using propidium-iodide staining and flow cytometry. Cells incubated with LMW-BCGF were also compared with control cells incubated with media alone. Leukemic BM mononuclear cells from six of nine (75%) patients cultured with LMW-BCGF showed increases in the percentage of cells in the S (DNA synthesis), G2 (premitosis), and M (mitosis) phases of the cell cycle ( Table 2 ). The median percentage of S + G2/M for these patient's cells preculture was 7.0%. Median percentage of S + G2/M for cells cultured for 3 days with LMW-BCGF was 9.8% as compared with 3.6% for cells cultured with media alone ( P i .03). All patients whose cells showed an increased percentage of S + G2/M also showed increased thymidine incorporation.
To determine if the cells responding to LMW-BCGF belonged to the leukemic population, BM cells from one patient (UPNO) were surface labeled with CD10+ and then stained with propidum iodide for cell-cycle analysis by a modification of the method of Hollander.12 Twenty-two percent of the BM cells were in either S or G2/M phases; of these cells, 96% were CDlO+, indicating that the responding cells belonged to the leukemic population (data not shown).
DISCUSSION
Most pediatric ALL patients belong to the BCP-ALL subclass. This subclass can be phenotypically defined by expression of the B-cell-restricted antigen CD19'' and also, in most cases, the Bell-associated antigen CDlO (CALLA). The BCP-ALL subclass includes early pre-B-ALL (CD19+/ CDlO'/CIgM -) and pre-B-ALL (CD19+/CDlO+/CIgM+), which together constitute approximately 80% to 85% of childhood ALL.
LMW-BCGF is able to stimulate proliferation of normal activated B cells as well as certain types of malignant B cell^.'^^^^.'^ We tested the effect of this lymphokine on proliferation of leukemic cells from children with BCP-ALL at diagnosis and relapse; cells from approximately 20 of 28 (71%) of BCP-ALL patients will form colonies when cultured with LMW-BCGF at 0.1 U/mL. This agrees with the findings of Uckun et al, ' who reported a similar percentage of patients responding in the clonogenic assay. In addition, in our study, cells from two patients with B-ALL formed lymphoblast colonies with LMW-BCGF. Cells from one of these patients (UPN 27) required exogenous LMW-BCGF for growth, whereas cells from the second patient (UPN 26) formed spontaneous colonies in the absence of the factor. Furthermore, we showed a dose-response effect of LMW-BCGF in stimulating colony growth. Mean plating efficiencies for BCP-ALL cells from three patients tested ranged from 0.03% (at 0.1 U/mL LMW-BCGF) to 0.32% (at 2.0 U/mL LMW-BCGF), with an apparent plateau occurring at the higher concentration. Colony cells from all patients tested had lymphoblast morphology and a phenotype (TdT+/ CD19+/CALLAi) identical to that of the patient's fresh leukemic cells. Except for four patients (three BCP-ALL and one B-ALL), there was no proliferation in cultures without added LMW-BCGF, indicating that factors present in FBS were alone unable to support proliferation. Further evidence for the leukemic origin of these colonies was obtained by culturing purified CD19' cells. These cells were able to proliferate and yield CDlO+/CD19+ colonies. Moreover, this finding indicates that LMW-BCGF is able to act directly on the leukemic cells and does not require the presence of accessory cells.
The wide variation among BCP-ALL patients in the numbers of leukemic colonies indicates heterogeneity at the leukemic progenitor cell level. Leukemic progenitor cells have been postulated to be the rapidly dividing stem cells that maintain expansion of the leukemic population. These cells may undergo partial differentiation to terminally dividing or nondividing progeny cells. The variability in response to LMW-BCGF may result from heterogeneity in number or affinity of receptors for this lymphokine (or both) on the progenitor cell, as suggested by Uckun et al, ' who reported a significant variation in specific binding of radioiodinated LMW-BCGF to BCP-ALL cells from different patients.
We further studied the effects of LMW-BCGFon proliferation of the bulk leukemic (progeny) population using thymidine incorporation and DNA quantitation (ie, propidiumiodide cell-cycle assay) as indicators of proliferation. Cells from 70% of patients tested showed significant enhancement in thymidine incorporation, which agrees with results of similar studies by Wormann et a16 and Uckun et aL7 Furthermore, these patients showed an increased percentage of replicating cells, as indicated by the increased fraction of cells in the S, G2, and M phases of the cell cycle, and these cells were CD10+ leukemic cells. Similarly, there was a correlation between the response of the leukemic cells to LMW-BCGF as measured by colony growth, thymidine incorporation, and cell-cycle status. This indicates, as Uckun et a1 suggested, that LMW-BCGF receptors are expressed on both the clonogenic BCP-ALL progenitor cells and the nonclonogenic leukemic progeny cells. ' Although the percentage of clonogenic cells was at most 0.6% (median 0.045%), the percentage of replicating cells in the cell-cycle studies was as high as 22% (median 9.8%) ( Table 2 ). This further indicates that not all cells responding to LMW-BCGF with increased proliferation are able to undergo a sufficient number of cell divisions (approximately five) to yield the 20-to 30-cell colony typically observed in our cultures. The leukemic cells with reduced proliferative potential are presumably the partially differentiated progeny of the leukemic progenitor cells; the former cells can give rise to the numerous clusters (4-to 16-cell aggregates) that we have observed in the clonogenic assay. The number of these cluster-forming cells is typically 2-to 10-fold that of the colony-forming cells.
In addition to our studies with LMW-BCGF, we compared the effects of this lymphokine with those of three recombinant lymphokines (rIL-2, rIL-3, and rIL-4) that influence proliferation of normal B-lineage lymphoid cells. Of these three lymphokines, rIL-3 stimulated the greatest degree of proliferation, both in colony and DNA synthesis assays. This finding agrees with a recent report by Uckun et all6 that BCP-ALL cells can express IL-3 receptors and proliferate in response to this factor. rIL-2 and rIL-4 had a lesser effect on DNA synthesis and did not support colony growth.
Our findings with regard to rIL-2 agree with those of Wormann et al," who reported that rIL-2 had minimal effects on DNA synthesis by leukemic BM cells from BCP-ALL patients. Several investigators'8'20 have shown that rIL-2, in the presence of normal PB lymphocytes (primarily T cells) as feeder cells, was able to enhance growth of leukemic BM cell colonies from BCP-ALL patients. In agreement with our finding, these investigators reported that IL-2 alone did not support colony growth, but that both IL-2 and feeder leukocytes were needed. The mechanism whereby feeder leukocytes stimulated ALL-cell proliferation in these cultures was not analyzed. Helper T cells in the feeder cells may have been stimulated by IL-2 to release other lymphokines, such as LMW-BCGF and IL-3, which were able to stimulate BCP-ALL colony. Similarly, Uckun et alzl originally reported that conditioned media from PHA-stimulated PB lymphocytes was able to support the growth of leukemic colonies from BCP-ALL. We are currently studying the interaction of these ILs (rIL-2, rIL-3, and rIL-4) with LMW-BCGF to identify possible synergistic effects on BCP-ALL proliferation.
We have thus confirmed previous studies of the effects of LMW-BCGF and rIL-3 on proliferation of BCP-ALL cells. Both of these lymphokines are able to support growth of leukemic clonogenic progenitor cells as well as nonclonogenic progeny cells. We also showed that BCP-ALL cells from a patient may respond with colony growth and increased DNA synthesis to more than one factor (eg, LMW-BCGF and IL-3), although some factors (IL-2, IL-4) alone appear unable to support clonogenic growth. Similar observations have been made for normal B-cell precursors,8-" further indicating the close relationship between these cells and BCP-ALL cells. Although LMW-BCGF-induced proliferation of leukemic clonogenic progenitor cells from most BCP-ALL patients appears to be short-term in the clonal assay, a few cultures contained colonies that continued to expand on refeeding with LMW-BCGF and media. Longterm cultures of BCP-ALL cells from these patients were established using LMW-BCGF to support initial proliferation of the cells. These leukemic cell lines require exogenous factor initially but later lose this requirement. This observation led us to investigate production of autocrine growth factors by these cells. Several of our BCP-ALL cell lines appear to produce autocrine growth-stimulatory activity which is also able to stimulate growth of BCP-ALL cells obtained directly from patients. We are currently examining these cell lines for production of LMW-BCGF and other growth factors. The presence of these factors would suggest that one mechanism of leukomogenesis could be the initiation of autocrine production of LMW-BCGF and/or other factors by B-cell precursors expressing the corresponding receptors. The requirement for exogenous growth factor by cultured leukemic cells could in some cases reflect low levels of endogenous factor production and a resulting cell-densitydependent growth pattern in culture, as we observed with our BCP-ALL cell lines and with fresh cells from some patients. We are further investigating the mechanisms for this exogenous factor-independent growth.
